Skip to main content

Tagged With "stem cell"

Blog Post

AAFA Urges Inclusion of Patient Voice in Analysis of Costly New Asthma Drugs

AAFA Community Services ·
Biologics are a new class of drugs that fight disease at the source . Instead of attacking symptoms, these drugs target diseases like asthma at a molecular level. These newer types of drugs are more expensive than older medicines. That is prompting public discussion on how to pay for them. The cost of caring for patients with the most severe forms of asthma represents a majority of asthma healthcare spending. In addition, asthma is a leading cause of missed time from work and school. Last...
Blog Post

Asthma and Allergy Research Review, April-June 2017

AAFA Community Services ·
The Asthma and Allergy Foundation of America will recap some of the top research on allergies and asthma every quarter. Here is a look at studies reported between April and June 2017. Learn why some children may not respond to asthma treatments, how testosterone may affect asthma and more.
Blog Post

FDA Approves a New Treatment Option for Those With Severe Asthma

AAFA Community Services ·
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Blog Post

FDA Approves Cinqair to Treat Severe Asthma

AAFA Community Services ·
FDA News Release FDA approves Cinqair to treat severe asthma For Immediate Release March 23, 2016 Inquiries Media Andrea Fischer 301-796-0393 Consumers 888-INFO-FDA Release The U.S. Food and Drug Administration today approved Cinqair (reslizumab) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current...
Blog Post

FDA Approves Dupixent® for Treatment of Asthma

AAFA Community Services ·
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post

FDA Approves FASENRA® Pre-Filled Auto-Injector Pen for Self-Administration

AAFA Community Services ·
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved the self-administration of FASENRA® (benralizumab) in a pre-filled, single-use auto-injector (the FASENRA Pen™).
Blog Post

FDA Will Consider Xolair for the Treatment of Nasal Polyps

AAFA Community Services ·
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Xolair® (omalizumab) for the treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to intranasal corticosteroids.
Blog Post

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

AAFA Community Services ·
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post

Preparing for Natural Disasters When You Have Asthma

AAFA Community Services ·
If you have asthma, natural disasters could affect your health in unexpected ways. Chronic medical conditions like asthma can become worse when wildfires, tornadoes, severe flooding or earthquakes occur. Asthma flare-ups during a disaster can happen because of: Allergens in the air (pollen, mold, etc.) Irritants in the air (dust, smoke) Losing access to your treatments due to evacuation Strong emotions (fear, anxiety) Now is a good time to create a disaster planning kit with your asthma in...
Blog Post

Study Shows a Difference Between the Effects of Controlled Burns vs. Wildfires

AAFA Community Services ·
Controlled burns are often used to help reduce and contain wildfires, but it turns out which burn is occurring can actually have an effect on your health, according to research presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).
Blog Post

Study Shows Mepolizumab to Be a Safe and Effective Long-Term Treatment Option for Severe Asthma

AAFA Community Services ·
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] Nucala (mepolizumab) study reports long-term safety data, consistent exacerbation reduction and improved asthma control New study showed one third of patients had no exacerbations on long-term treatment with Nucala GlaxoSmithKline plc (GSK) today presented new data from the longest study of an anti-IL5 biologic treatment in severe...
Blog Post

Infant Gut Bacteria Affects Allergy and Asthma Risk

AAFA Community Services ·
The microbial communities, or microbiota, that naturally colonize the digestive tract in very young infants can affect their risk of later developing childhood allergies and asthma.
Blog Post

Living With Asthma in Birmingham, Alabama, the #8 Asthma Capital

AAFA Community Services ·
For many, asthma is caused by an allergic reaction to something. This is called allergic asthma is the most common. But a small number of people with asthma have “non-allergic asthma.” Lynn Johnson is part of this group. Lynn developed non-allergic asthma seven years ago, as an adult.
Blog Post

LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced

AAFA Community Services ·
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Image

Ready-set-go!

K8sMom2002 ·
Ready-set-go!
Blog Post

Cleaning Your Hands With Soap Vs. Hand Sanitizer: What Is Best to Protect Yourself From COVID-19 and Other Illnesses?

AAFA Community Services ·
Keeping your hands clean is one of the easiest ways to reduce the spread of the new coronavirus that causes COVID-19 . It can also help help protect you from flu, colds and other respiratory infections . It also helps prevent foodborne illnesses (such as salmonella) while cooking. One study shows people touch their faces on an average of 23 times an hour. 1 Your hands come in contact with many germs, and when you touch your face, you increase your chances of getting sick. Keeping them clean...
Blog Post

FDA Accepts Biologics License Application for Xolair® Prefilled Syringe for Self-Administration

AAFA Community Services ·
Novartis today announced that the US Food and Drug Administration (FDA) accepted the company's supplemental Biologics License Application (sBLA) for a new self-administration option for Xolair® (omalizumab) across all approved US indications. If approved, Xolair prefilled syringe would become available for either self-administration by select patients or administration by their caregivers.
Blog Post Featured

Brace Yourselves: The Biggest Week for Asthma Attacks Is Coming

AAFA Community Services ·
Every September, asthma hospitalizations rise. Doctors see more people with asthma episodes and attacks. The third week of the month is the worst. It is called the September Asthma Epidemic or Asthma Peak Week. Everyone with asthma needs to be prepared.
Blog Post

Leading Patient Advocacy Organizations Join Forces to Launch National Program Aimed at Raising Awareness of Severe Form of Asthma

AAFA Community Services ·
Allergy & Asthma Network (AAN) and the Asthma and Allergy Foundation of America (AAFA) today announced the launch of Be the Boss of Your Asthma, a national educational program that aims to raise awareness of severe eosinophilic asthma – or S.E.A. – a serious and often hard-to-control form of asthma.
Blog Post

FDA Approves Xolair® (Omalizumab) Prefilled Syringe for Self-Injection

AAFA Community Services ·
Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection in appropriate patients across all approved US indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
Blog Post Featured

How Can You Tell the Difference Between COVID-19, a Cold, the Flu, Allergies and Asthma?

AAFA Community Services ·
Cold and flu season is here, and the new coronavirus that causes COVID-19 is still spreading. With every cough or sniffle, you may wonder if it’s asthma or allergies, the flu, the common cold or even COVID-19. But how can you tell the difference? The Asthma and Allergy Foundation of America (AAFA) has created a respiratory symptoms chart to help you recognize the difference between these conditions. Click to see larger image (English) Click to see larger image (Spanish) Asthma Symptoms...
Blog Post Featured

Coronavirus (COVID-19): What People With Asthma Need to Know

AAFA Community Services ·
Updated 5/28: The new coronavirus that causes COVID-19 is still highly active through the U.S. Read the current recommendations for people with asthma including symptoms, wearing masks, and new guidelines if your fully vaccinated.
×
×
×
×